# Lupus Erythematosus, Systemic FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/lupus-erythematosus-systemic

> 9 upcoming FDA catalysts in lupus Erythematosus, Systemic: litifilimab (BIIB) on Dec 2026 (topline data readout); cenerimod 4 mg (VTRS) on Dec 2026 to Mar 2027 (topline data readout); cenerimod 4 mg (VTRS) on December 2026 (primary completion); cenerimod 4 mg (VTRS) on Mar to Jun 2027 (topline data readout); and 5 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | delayed | "NCT04961567 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04961567)) |
| September 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | delayed | "NCT04895241 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895241)) |
| Dec 2026 | [Litifilimab topline data readout](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | scheduled | "•The Company expects to announce top line data from both TOPAZ-1 and TOPAZ-2 Phase 3 studies, evaluating litifilimab in SLE, in the first half of December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm)) |
| Dec 2026 to Mar 2027 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05672576)) |
| December 2026 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05672576)) |
| Mar to Jun 2027 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05648500 (A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648500)) |
| March 2027 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05648500 (A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648500)) |
| Aug to Nov 2028 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Erythematosus, Systemic | scheduled | "NCT07751848 (A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07751848)) |
| August 2028 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Erythematosus, Systemic | scheduled | "NCT07751848 (A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-25 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07751848)) |
| Dec 2028 to Mar 2029 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Lupus Erythematosus, Systemic | scheduled | "NCT07438496 (A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438496)) |
| December 2028 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Lupus Erythematosus, Systemic | scheduled | "NCT07438496 (A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438496)) |

## Drugs

- [Litifilimab](https://sec-api.dev/pdufa/litifilimab) (BIIB)
- [Cenerimod 4 mg](https://sec-api.dev/pdufa/cenerimod) (VTRS)
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [IMAAVY (nipocalimab)](https://sec-api.dev/pdufa/nipocalimab) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/lupus-erythematosus-systemic.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lupus Erythematosus, Systemic FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/lupus-erythematosus-systemic

```bibtex
@misc{secapidev_indications_lupus_erythematosus_systemic_20261116,
  title        = {Lupus Erythematosus, Systemic FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/lupus-erythematosus-systemic}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_lupus_erythematosus_systemic_20261116","title":"Lupus Erythematosus, Systemic FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/lupus-erythematosus-systemic","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
